Johnston DA - Search Results

1

Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.

Ko SC, Gotoh A, Thalmann GN, Zhau HE, Johnston DA, Zhang WW, Kao C, Chung LW. Ko SC, et al. Among authors: johnston da. Hum Gene Ther. 1996 Sep 10;7(14):1683-91. doi: 10.1089/hum.1996.7.14-1683. Hum Gene Ther. 1996. PMID: 8886839

2

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.

Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW. Thalmann GN, et al. Among authors: johnston da. J Natl Cancer Inst. 1996 Jun 19;88(12):794-801. doi: 10.1093/jnci/88.12.794. J Natl Cancer Inst. 1996. PMID: 8637045

3

The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer.

Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordoñez NG, Troncoso P, Navone NM. Fizazi K, et al. Among authors: johnston da. Clin Cancer Res. 2002 Mar;8(3):775-81. Clin Cancer Res. 2002. PMID: 11895908

4

Establishment of two human prostate cancer cell lines derived from a single bone metastasis.

Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Navone NM, et al. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2493-500. Clin Cancer Res. 1997. PMID: 9815652

5

Aneuploidy index in blood: a potential marker for early onset, androgen response, and metastasis in human prostate cancer.

Ozen M, Hopwood VL, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S. Ozen M, et al. Among authors: johnston da. Urology. 1999 Feb;53(2):381-5. doi: 10.1016/s0090-4295(98)00487-7. Urology. 1999. PMID: 9933059

6

p53 expression in dedifferentiated chondrosarcoma.

Simms WW, Ordóñez NG, Johnston D, Ayala AG, Czerniak B. Simms WW, et al. Cancer. 1995 Jul 15;76(2):223-7. doi: 10.1002/1097-0142(19950715)76:2<223::aid-cncr2820760210>3.0.co;2-4. Cancer. 1995. PMID: 8625095

7

Prostate cancer detection: relationship to prostate size.

Chen ME, Troncoso P, Johnston D, Tang K, Babaian RJ. Chen ME, et al. Urology. 1999 Apr;53(4):764-8. doi: 10.1016/s0090-4295(98)00574-3. Urology. 1999. PMID: 10197853

8

Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer.

Babaian RJ, Kojima M, Ramirez EI, Johnston D. Babaian RJ, et al. J Urol. 1996 Aug;156(2 Pt 1):432-7. doi: 10.1097/00005392-199608000-00027. J Urol. 1996. PMID: 8683696

9

The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy.

Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA HA Jr. Babaian RJ, et al. Among authors: johnston da. J Urol. 2001 Mar;165(3):757-60. J Urol. 2001. PMID: 11176461

10

Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml.

Okihara K, Fritsche HA, Ayala A, Johnston DA, Allard WJ, Babaian RJ. Okihara K, et al. Among authors: johnston da. J Urol. 2001 Jun;165(6 Pt 1):1930-6. doi: 10.1097/00005392-200106000-00021. J Urol. 2001. PMID: 11371884

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

352 results

Search Page

Filters